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able replacement strategies for such diseased trachea,
the research into tracheal transplantation is of impor-
tance. We previously studied graft viability,1,2 rejection
reaction,3 minimal immunosuppression,4,5 and the
reconstruction range2,6-9 in tracheal allotransplantation
for eventual clinical use in human beings and obtained
satisfactory results. The shortage of donor trachea
remains a major obstacle, although transplantation of
the trachea is considered to be the preferred method for
the reconstruction of extensive tracheal defects in the
future. Previously, we investigated the maximal period
of cryopreservation for viable tracheal isografts to help
solve this problem.10 As a result, cryopreservation of
the trachea has been recognized to induce the degener-
ation of both the cartilage and epithelium. The permis-
sible period of cryopreservation for tracheal isografts is
considered to be 3 months because the cartilage showed
irreversible damage after that point.10 We also investi-
gated the limits of warm ischemia time before 3-month
cryopreservation for viable tracheal isografts and found
this period to be 18 hours in rats (unpublished data).
A long segment of the trachea is often affected bymalignant diseases or by benign stenoses of the air-
way caused by a traumatic, congenital, inflammatory,
or iatrogenic lesion. Because of the current lack of suit-
Objective: We evaluated the feasibility of discordant xenotransplantation of
the cryopreserved trachea with intermittent immunosuppression to help
solve the shortage of donor tracheas.
Methods: Two experiments were performed with heterotopic transplantation
models in 14 guinea pigs and 85 rats. So that the minimal dose of FK506 for
viable fresh xenografts could be determined, FK506 was given in escalating
doses (0, 1.5, 2.5, and 3.5 mg/kg) for recipient animals after xenogeneic
transplantation. With the goal of obtaining a long-term survival of the
xenografts, the effect of cryopreservation on xenografts was assessed and
thereafter different cycles of immunosuppression every third week were
evaluated in fresh or cryopreserved xenografts in the second experiment.
Results: An FK506 dosage of more than 2.5 mg/kg per day was much more
effective than smaller dosages, as demonstrated by morphologic assessment.
A higher dosage of FK506 potentially delayed the rejection of xenografts
and can thus maintain tracheal xenograft viability for less than 4 weeks in rat
recipients. In experiment 2, the cryopreserved xenografts showed less histo-
logic viability than fresh xenografts but greater patency of the lumen. The
patency of cryopreserved xenografts was favorably maintained for a longer
period than that of fresh xenografts with either the same number or more
cycles of immunosuppression.
Conclusions: We conclude that the synergistic effect of cryopreservation and
adequate intermittent immunosuppression may enable tracheal xenografts to
remain viable over longer periods. (J Thorac Cardiovasc Surg 2001;121:241-8)
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These periods of preservation could therefore help us to
solve the severe shortage of human tracheal tissue. 
Xenogeneic cryopreserved tracheas are an appealing
alternative to tracheal allografts for transplantation
because of the potentially unlimited supply of tracheas
for use in human beings. Guinea pig tracheal
xenografts in rats have been the subject of relatively
few studies. Earlier, we observed that a short course of
immunosuppression with FK506 significantly retains
the viability of rat tracheal allograft.11 Several investi-
gators have also reported cryopreservation to reduce
the tracheal antigenicity.12,13 We thus tried to elucidate
the feasibility of the discordant xenotransplantation of
cryopreserved tracheas using a short course of
immunosuppression. The use of cryopreserved tracheal
xenografts could directly help to solve the shortage of
donors.
Materials and methods
Animals, anesthesia, and harvesting of tracheas.
Fourteen male guinea pigs and 85 male Brown Norway rats
between 10 and 12 weeks of age and weighing approximately
200 to 250 g were all premedicated with anesthetic ether. The
animals were placed in the supine position and anesthetized
with the intraperitoneal administration of sodium pentobarbi-
tal (10 mg/kg). Either harvesting or transplantation was per-
formed with the animals breathing spontaneously without an
endotracheal tube. The 14 donor guinea pigs and the 1 donor
Brown Norway rat were put to death with an intraperitoneal
overdose of pentobarbital and were left at room temperature
(24°C). After the donor animals were killed, the whole trachea
was identified through a midline cervical to sternal incision
and excised in continuity. Thereafter, the wound was closed in
the usual fashion. The harvested trachea was trimmed off in 5-
ring segments. As a result, 5 or 6 tracheal segments consisting
of 5 rings were harvested from each donor animal. All animals
received humane care in compliance with the “Guide for the
Care and Use of Laboratory Animals” published by the
National Institutes of Health (NIH Publication No. 85-23,
revised 1985).
Cryopreservation and grafting. The tracheal segments
were then either used as fresh grafts or immediately stored in
a plastic sterile tube filled with the freezing solution. The
preservative solution in which the grafts were immersed con-
tained a balanced buffered salt solution with L-glutamine
(RPMI1640 medium; JRM Biosciences, Lenexa, Kan) with a
final concentration of 20% fetal calf serum and 10% dimethyl
sulfoxide as the cryoprotectant. The plastic tube containing
the specimen was then stored in a Bicell biofreezing vessel
(Nihon Freezer Co, Ltd, Tokyo, Japan) after cooling at 4°C
for an hour and was subsequently stored in a deep freezer at
–80°C. The Bicell biofreezing vessel has the ability to cool at
a rate of approximately 1°C per minute in a deep freezer until
reaching –80°C.10 Cryopreserved xenografts were thawed in
an incubator for 15 minutes at 37°C for grafting. All
xenografts were stented over a silicone rod measuring 1.35
mm in diameter (ATOM, Inc, Tokyo, Japan). A silicone rod
was used to prevent the omentum from intruding into the
graft. A modified version of the heterotopic tracheal trans-
plant model with omental wrapping has been used for rats
because this model showed the same healing course as an
orthotopic transplantation model in our previous experi-
ments.3,5,10 The recipient animals were placed in a supine
position. Through a small upper midline laparotomy, the
greater omentum was delivered into the wound. The anterior
layer of the omentum was opened, and the tracheal transplant
was then completely enveloped. The omentum and the
enclosed transplant were then returned to the peritoneal cav-
ity, and the wound was closed.
Experimental design. Two experiments were performed
to assess the utility of the cryopreserved xenogeneic trachea.
The minimal dose of FK506 for viable fresh xenografts was
determined by gradually increasing administrations of FK506
for the recipient animals in the first experiment. Different
doses of FK506 were thus administered intramuscularly for
only 3 consecutive days after heterotopic tracheal xenotrans-
plantation. Syngeneic transplantation without any other treat-
ment was performed in 4 rats and the isografts were evaluat-
ed 4 weeks after surgery (group 1). The remaining 48 animals
that underwent a xenogeneic transplantation were randomly
allocated into 4 treatment groups as follows: group 2 (n = 12),
no immunosuppression; group 3 (n = 12), 1.5 mg/kg dose of
FK506; group 4 (n = 12), 2.5 mg/kg dose of FK506; and
group 5 (n = 12), 3.5 mg/kg dose of FK506. To histological-
ly observe the xenogeneic immune response and also to
determine the minimal dose of FK506 for viable tracheal
xenografts, we performed a second laparotomy to retrieve the
transplants 1, 2, or 4 weeks after surgery, thereby creating
subgroups of a, b, and c, respectively (Fig 1, A).
With the aim of achieving long-term xenograft survival, dif-
ferent cycles of immunosuppression every third week were
evaluated with fresh or cryopreserved xenografts used in the
second experiment. One cycle of immunosuppression was
designed to administer a minimal dose of FK506, as deter-
mined in experiment 1, for 3 consecutive days. The donor
grafts were randomly assigned to 5 groups. Fresh (group 6: n
= 8) and cryopreserved (group 7: n = 8) xenografts that had
both undergone 1 cycle of immunosuppression were evaluat-
ed 3 weeks after surgery, and the effect of cryopreservation on
the xenograft was assessed. Two (group 8: n = 8) and 3 (group
9: n = 4) cycles of the treatment for fresh xenografts and 2
cycles of treatment for cryopreserved xenografts (group 10: n
= 4) were performed after transplantation to evaluate the long-
term survival of the xenograft. The viability of the transplants
was evaluated 8 weeks after transplantation in groups 8 and 9
and 11 weeks after surgery in group 10 (Fig 1, B). 
Morphologic assessment. All tissue specimens were fixed
in 10% formalin. Microscopic slides were made from cross
sections of the midportion of the tracheal segment and adher-
ent omentum and then were routinely stained with hema-
toxylin and eosin. Thereafter, all specimens were examined
by light microscopy. We attempted to quantify the viability of
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the heterotopically grafted trachea by objectively calculating
the percent patency of the cross-sectional area (CSA) of the
middle part in the graft and subjectively evaluating the mor-
phology of epithelium and cartilage. All assessments were
performed in a blinded fashion.
Patency. The graft percent patency was expressed as a pro-
portion of the CSA of the xenograft on the observed day after
surgery to the same graft before surgery. The CSA was cal-
culated by the following formula: CSA = a/2 × b/2 × π, where
“a” was the transverse diameter and “b” was the sagittal
diameter.2,4
Epithelial viability. Epithelial viability was evaluated
according to the following grading system: 0 = no epithelium,
1 = single-layer nonciliated epithelium, 2 = multilayer non-
ciliated epithelium, and 3 = normal mucociliary epithelium.
The epithelium of the grafts was assessed as a ratio of the
epithelial score on a microscopic slide.3,5,10
Cartilage viability. In experiment 1, the viability of the car-
tilage of each transplant was graded semiquantitatively from
0 to 3, with 0 indicating severe changes (necrotic area > 70%
of a microscopic visual field), 1 indicating moderate changes
(30% < necrotic area < 70%), 2 indicating mild changes
(necrotic area < 30%), and 3 indicating the absence of any
abnormalities.3,5,6 More detailed data were investigated in
experiment 2. The ratio of chondrocytes possessing viable
nuclei in the cartilage of each transplant was calculated after
carefully counting the number of all chondrocytes in each
high-power field on a microscopic slide. A viable chondro-
cyte nucleus was regarded as richly stained and possessing a
clear nucleus membrane.10 The score of cartilage dislocation
was then graded semiquantitatively from 0 to 3, with 0 indi-
cating the absence of any abnormalities, 1 indicating mild
changes (incidence of cartilage dislocation < 30% of a micro-
scopic visual field), 2 indicating moderate changes (30% <
incidence of dislocation < 70%), and 3 indicating severe
changes (incidence of dislocation > 70%) in experiment 2.
Statistical analysis. All data were presented as the mean ±
standard deviation of the mean. A statistical analysis was per-
formed with the use of the paired Student t test.
Results
Experiment 1. So that the minimal dose of FK506
for viable fresh xenografts could be determined, esca-
lated doses of FK506 (0, 1.5, 2.5 and 3.5 mg/kg) were
administered to recipient animals after xenogeneic
transplantation. 
Animals. All animals survived the experimental pro-
tocol period. The weight of the recipient rats in group
5 decreased about 5% until 2 weeks after surgery but
had recovered to the control level by 4 weeks after the
operation. No problem regarding weight was observed
in other groups. 
Macroscopic findings. All tracheal grafts were
wrapped firmly by the omentum. Grossly, all free tra-
cheal isografts appeared normal and also preserved
their luminal rigidity, whereas the xenografts that
underwent the lower dosage FK506 treatment did not
demonstrate the same findings. The graft percent
patency of groups 2c and 3c was significantly worse
than that of the control group (Table I). The patency of
groups 4c and 5c showed a better trend, according to a
stepwise increase of dosage of FK506, than that of
group 2c (group 2c vs 4c, P = .0592; 2c vs 5c, P =
.0511) and did not demonstrate any significant differ-
ence from the control group (Fig 2). Mucoid fluid filled
the lumen of almost all isografts in group 1 but not in
groups 2 to 5.
Microscopic findings. Both a lower dosage of
FK506 and a long-term observation apparently
resulted in an irreversible deterioration of the tra-
cheal xenografts. The epithelium of the xenografts in
groups 2 and 3 was almost denuded by 2 weeks after
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Fig 1. A, Design of experiment 1. B, Design of experiment 2.
The arrowhead shows 1 cycle of immunosuppressive therapy
with FK506 for 3 consecutive days.
A
B
the operation. The score in group 2 was significantly
worse than that in groups 4 and 5 (groups 2b vs 4b,
P = .0209; 2a vs 5a, P = .0009; 2b vs 5b, P = .0119;
2c vs 5c, P = .0202). In addition, each epithelial score
in group 3 was significantly worse than that in groups
4 and 5 (groups 3b vs 4b, P = .0155; 3a vs 5a, P =
.0225; 3b vs 5b, P = .0096; 3c vs 5c, P = .0202) (Fig
3, A). In the interstitium, extensive hemorrhaging was
seen in all groups 1 week after the operation.
Submucosal thickening caused by fibrosis and necro-
sis gradually increased in the lower dosage FK506
groups by 4 weeks after surgery, whereas the same
findings decreased in the higher dosage groups. Some
xenografts of the higher dosage groups first showed a
high infiltration of mononuclear cells 4 weeks after
the operation. Regarding cartilage viability, the semi-
quantitative score in groups 2 and 3 was significantly
worse than that in groups 4 and 5 (groups 2b vs 4b, P
= .0060; 2b vs 5b, P = .0138; 2c vs 4c, P = .0163; 2c
vs 5c, P = .0032; 3c vs 5c, P = .0377) (Fig 3, B).
According to the length of the observation period, the
epithelial score showed a significant exacerbation in
the subgroups of group 5 (groups 5a vs 5c, P = .0462;
5b v 5c, P = .0082) (Fig 3, A), and the cartilage score
showed a significant exacerbation in the subgroups of
group 2 (groups 2a vs 2b, P = .0060; 2a vs 2c, P =
.0032) (Fig 3, B). Four weeks after surgery, the
epithelial score in groups 2c, 3c, and 5c was signifi-
cantly worse than that of the control group (2.362 ±
0.189) (P = .0001, .0004, and .0033, respectively),
and the cartilage score in group 2c was significantly
worse than that of the control group (2.750 ± 0.500)
(P = .0029). The xenografts administered FK506 in
doses of 2.5 to 3.5 mg/kg (groups 4 and 5) showed a
moderate grade of degeneration in the epithelium but
possessed single-layer and/or multilayer nonciliated
epithelium in some parts and low-grade degeneration
of the cartilage 4 weeks after surgery (Fig 2).
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Table I. Percent patency of tracheal grafts in experiment 1
Groups Transplantation Dosage of FK506 (mg/kg) Patency (%)
1 (control) Syngeneic 0 100
2c Xenogeneic 0 48.85 ± 5.500*
3c Xenogeneic 1.5 57.81 ± 8.559*
4c Xenogeneic 2.5 80.40 ± 19.95
5c Xenogeneic 3.5 84.10 ± 18.00
Data are presented as mean ± standard deviation of the mean. 
*The percent patency in each group was significantly worse than that in the control group (group 1 vs 2c, P = .0003; 1 vs 3c, P = .0134).
Table II. Comparison between fresh and cryopreserved tracheal xenografts 3 weeks after surgery
Viable Cartilage Mononuclear
Graft Epithelial chondrocyte dislocation cell infiltration
Groups status Patency (%) score ratio score score
6 Fresh 65.59 ± 21.98 0.650 ± 0.382 0.313 ± 0.139 0.750 ± 0.886 1.500 ± 1.195
7 Cryop 82.48 ± 18.28 0.325 ± 0.437 0.161 ± 0.079* 0† 0.750 ± 0.463
Data are presented as mean ± standard deviation of the mean. Cryop, Cryopreserved.
*The chondrocyte ratio in group 7 was significantly lower than that in group 6 (P = .0098).
†The cartilage dislocation score in group 7 was significantly lower than that in group 6 (P = .0479).
Table III. Morphologic features of tracheal xenografts receiving multiple cycles of immunosuppression
Viable Cartilage Mononuclear
Graft Tx Postop Patency Epithelial chondrocyte dislocation cell infiltration
Groups status cycles weeks (%) score ratio score score
8 Fresh 2 8 78.03 ± 16.54 0.025 ± 0.071 0.259 ± 0.164 0.250 ± 0.463 1.625 ± 0.744
9 Fresh 3 8 84.36 ± 18.85 0 0.473 ± 0.155 0.125 ± 0.354 0
10 Cryop. 2 11 85.98 ± 17.85 0.110 ± 0.143 0.317 ± 0.128 0.250 ± 0.463 0.750 ± 0.500
Data are presented as mean ± standard deviation of the mean. Tx, Treatment; Postop, postoperative; Cryop, cryopreserved.
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Fig 2. Histologic findings in fresh xenografts 4 weeks after surgery in group 5c. A single-layer and multilayer non-
ciliated epithelium is recognized. The cartilage has mostly viable chondrocyte nuclei. Mononuclear cell infiltration
is only slightly seen. Submucosal thickening is seen, but the patency of the graft is well maintained. (Hematoxylin
and eosin stain; original magnification, ×100.)
Fig 3. A, The epithelial score (mean ± standard deviation of the mean) of tracheal xenografts in groups 2 to 5. 
B, The cartilage score (mean ± standard deviation of the mean) of tracheal xenografts in groups 2 to 5. 
A
B
Experiment 2. With the goal of obtaining long-term
survival of the xenografts, the effect of cryopreserva-
tion on xenografts was assessed and thereafter different
cycles of immunosuppression every third week were
evaluated in fresh or cryopreserved xenografts in the
second experiment.
Animals. All animals received different cycles of
immunosuppression consisting of an FK506 dose of
2.5 mg/kg determined in experiment 1, and all survived
for the entire experimental protocol period. No problem
regarding the weight of any group was observed. 
Macroscopic findings. The omentum was wrapped
firmly around the tracheal xenografts in all rats.
Grossly, cryopreserved tracheal xenografts in group 10
appeared to be almost normal and their luminal rigidi-
ty was preserved, whereas fresh xenografts in group 6
were swollen and the lumen showed a slight narrowing.
The percent patency of the cryopreserved xenografts
(group 7) was slightly better than that of the fresh
xenografts (group 6) 3 weeks after surgery (Table II).
Regarding the groups that were observed long term, the
percent patency of the cryopreserved xenografts in
group 10 was slightly higher than that of the fresh
xenografts in group 8 (Table III). No mucoid fluid
filled the lumen of any xenografts in groups 6 to 10
because the mucociliated epithelium and tracheal
glands had been completely obliterated.
Microscopic findings. Three weeks after surgery, the
viable chondrocyte ratio of the cryopreserved xenografts
was significantly worse than that of the fresh grafts, and
the same trend was also seen in the epithelial score. On
the other hand, the cryopreserved xenografts showed a
significantly better cartilage dislocation score than fresh
grafts, and the same trend was also seen for the mononu-
clear cell infiltration score (Table II). In the groups
observed long term, the histologic findings of the cryo-
preserved xenografts (group 10) were almost the same as
those of the fresh xenografts (groups 8 and 9), despite a
longer period of observation in group 10. Fresh
xenografts showed moderate degeneration of the epithe-
lium in group 6 and slightly higher degeneration in
groups 8 and 9, despite receiving multiple cycles of
treatment. On the other hand, the cryopreserved
xenografts showed some single-layer nonciliated epithe-
lium, but none of them completely lost their epithelium
despite prolonged observation (Fig 4). Submucosal
thickening and mononuclear cell infiltration were often
seen in the fresh xenografts of groups 6 and 8. Viable tra-
cheal glands were seen in some cryopreserved
xenografts. Regarding the cartilage, no difference was
seen in the viable chondrocyte ratio and the cartilage dis-
location score between the fresh (groups 8 and 9) and
cryopreserved (group 10) xenografts in the groups
observed long term (Table III).
Discussion
The mechanism for host rejection of xenografts dif-
fers from that of allografts. Humoral responses play an
important role in discordant xenograft rejection. Only
immunosuppressive agents, therefore, must be inca-
pable of reducing or delaying the rejection of
xenografts. However, several investigators have already
described that an appropriate immunosuppressive regi-
men can prolong xenograft survival. Anti-rat lympho-
cyte serum alone significantly prolonged xenograft
functional survival, and no hyperacute rejection reac-
tion occurred in a pig-to-rat xenotransplantation
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Fig 4. Histologic findings of cryopreserved xenografts 11
weeks after surgery in group 10 (undergoing 2 cycles of
immunosuppression). A single-layer and multilayer noncili-
ated epithelium is extensively recognized. The cartilage has
viable chondrocyte nuclei for the most part. Mononuclear cell
infiltration is only slightly seen. Some submucosal thickening
is seen but the patency of the graft is well maintained.
(Hematoxylin and eosin; original magnification, ×200.)
model.14,15 Valdivia and associates16 reported FK506 to
potentially suppress antibody production in hamster-to-
rat xenotransplantation. Hebebrand and colleagues17
showed FK506 to be a better immunosuppressive agent
than RS61443, which they expected for xenograft sur-
vival because of its mechanism of action to reduce nat-
ural antibodies. For these reasons, we also selected
FK506 alone as an immunosuppressant in these exper-
iments. We designed these experiments using the same
protocol of consecutive 3-day administrations of
FK506 as we had previously used in rat allotransplan-
tation models.11
A rapid rejection was seen in all rats that were not
immunosuppressed in group 2, but a viable graft sur-
vival was achieved with adequate FK506 immunosup-
pression. A dosage of more than 2.5 mg/kg per day was
much more effective than any smaller doses, as demon-
strated by a morphologic assessment in experiment 1.
A higher dosage of FK506 may delay the rejection of
xenografts and maintain tracheal xenograft viability for
less than 4 weeks in rat recipients because a high infil-
tration of mononuclear cells was first seen in well-
maintained xenografts 4 weeks after surgery. We there-
fore designed the immunosuppression every third week
for fresh or cryopreserved xenografts in the second
experiment. The present findings indicate that the
rejection of adult guinea pig xenografts in rats is sensi-
tive to FK506, suggesting an important role for T cells
in the rejection process. In addition, this dosage may be
tolerable for the health of the recipient, as demonstrat-
ed by the minimal weight changes of animals.
Tze, Tai, and Chung14 reported that hyperacute rejec-
tion between discordant species does not occur in tis-
sue xenotransplantation, probably because of low nat-
ural antibody titers. In general, cellular rejection is
considered to be closely associated with tissue
xenografts. There is also no firm evidence that any
hyperacute rejection of tracheal xenografts occurred in
our series. The detailed mechanism of tissue xenograft
rejection remains unclear. Another mechanism of rejec-
tion added to the T cell–derived response may exist in
tracheal xenotransplantation because the findings of
xenograft rejection were slightly more severe than
those of allograft rejection in our studies.3-5 A primitive
immunoreaction may be associated with tracheal xeno-
transplantation, as evidenced by the effect of intensive
immunosuppression.18
The epithelial morphology is reported to be closely
associated with the rejection reaction in tracheal trans-
plantation inasmuch as the epithelium has a strong anti-
genicity.19,20 The epithelium always disappears after
heterotopic transplantation without immunosuppres-
sion. Thus, when the epithelium remains in tracheal
allografts receiving immunosuppression, it means that
immunosuppressive therapy has been effective.3-6
However, a donor epithelium is not necessarily needed
in orthotopic tracheal transplantation because the donor
epithelium is denuded after transplantation and the
lumen of the graft is then covered with a migrated
recipient epithelium.12 The assessment of the cartilage
is more important than the assessment of the donor
epithelium, which is considered to sensitively reflect
graft viability in the heterotopic tracheal transplanta-
tion models, because the donor cartilage is not replaced
by the recipient cartilage.3-6 We therefore studied in
detail the donor cartilage, which plays an important
role in keeping luminal rigidity. We also assessed the
cartilage dislocation, which is closely associated with
the percent patency.1-10 We gained seemingly conflict-
ing results: for instance, the cryopreserved xenografts
in group 7 showed less histologic viability than fresh
xenografts in group 6, whereas the percent patency of
their lumen indicated paradoxic findings. Cryo-
preserved xenografts did not show any cartilage dislo-
cation despite a lower viability of chondrocyte. The
cartilage dislocation is caused by the cellular infiltra-
tion and fibrosis and is not associated with the viable
chondrocyte ratio.10 Cryopreservation has a degenera-
tive effect on both the epithelium and cartilage and can
potentially lead to a reduced antigenicity in both com-
ponents.10,12,13 Perhaps the low antigenicity caused by
cryopreservation may reduce cellular infiltration and
consequently cartilage dislocation may not occur. The
fact that the patency of cryopreserved xenografts 11
weeks after surgery was almost equivalent to that of
fresh xenografts with either the same number of cycles
or more immunosuppression 8 weeks after surgery, and
was well maintained, may support our speculation. 
We have thus shown that prolonged survival of dis-
cordant cryopreserved tracheal xenografts can be
achieved with FK506 monotherapy. The synergistic
effect of cryopreservation and adequate intermittent
immunosuppressive therapy may play an important
role in maintaining xenograft viability for long periods.
Further studies are needed, however, to elucidate the
mechanism of tracheal xenograft rejection, to maintain
viable graft stability, and to investigate the usefulness
of the potential source of xenografts, for example,
porcine or primate, for clinical use in human beings.
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